Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma
Crossref DOI link: https://doi.org/10.1007/s12185-016-2070-7
Published Online: 2016-07-26
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Iida, Shinsuke
Tobinai, Kensei
Taniwaki, Masafumi
Shumiya, Yoshihisa
Nakamura, Toru
Chou, Takaaki
Funding for this research was provided by:
Ono Pharmaceutical Co., Ltd.
License valid from 2016-07-26